Education
About Us
Working with TipRanks
Follow Us
Alligator Bioscience AB (GB:0RK9)
LSE:0RK9
0RK9 Stock Chart & Stats
kr0.29
kr0.00(0.00%)
At close: 4:00 PM EST
kr0.29
kr0.00(0.00%)
Day’s Range― - ―
52-Week Rangekr0.17 - kr55.87
Previous CloseN/A
Volume0.00
Average Volume (3M)6.90K
Market Cap
kr99.15M
Enterprise Valuekr4.97M
Total Cash (Recent Filing)kr62.20M
Total Debt (Recent Filing)kr60.41M
Price to Earnings (P/E)―
Beta-0.05
Next Earnings
May 05, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.66
Shares Outstanding534,516,970
10 Day Avg. Volume9,644
30 Day Avg. Volume6,900
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)1.35
Price to Sales (P/S)18.04
P/FCF Ratio-0.06
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-1.75
Revenue Forecast (FY)kr23.80M
Bulls Say, Bears Say
Bulls Say
Partnering / Licensing Revenue ModelA partnering/licensing business model is capital-efficient for a clinical-stage biotech: it enables milestone and royalty upside while shifting late‑stage costs to partners. Over 2–6 months this reduces cash runway sensitivity and preserves upside if programs attract partners.
Focused Antibody Immunotherapy ExpertiseA clear scientific focus on antibody-based immunotherapies and immune co-stimulatory pathways supports durable competitive positioning in oncology R&D. Specialized expertise improves likelihood of valuable assets for out-licensing or partnerships in a growing immuno-oncology market.
Lean Organizational StructureA small headcount implies lower fixed overhead and potential for capital efficiency relative to larger peers. For a licensing-focused biotech, a lean team helps stretch limited resources, allowing management to prioritize R&D and partnering activities without large structural costs.
Bears Say
Very High Cash BurnSustained, very large negative operating and free cash flow creates structural reliance on external financing. Over coming months this elevates refinancing and dilution risk, constrains strategic optionality, and pressures timing/terms of potential partnering or licensing deals.
Weakened Balance Sheet & Rising DebtMaterial erosion of equity and stepped-up debt raise leverage and financial fragility. Higher indebtedness with minimal capital buffers limits flexibility, increases refinancing and covenant risk, and weakens negotiating power with potential partners or acquirers.
Sharp Revenue Collapse And Persistent LossesA near-total revenue drop alongside ongoing operating losses signals structural volatility in recognized collaborations or milestone timing. This undermines internal funding prospects, raises uncertainty about commercial traction, and lengthens the time to self-sustaining profitability.
Alligator Bioscience AB News
0RK9 FAQ
What was Alligator Bioscience AB’s price range in the past 12 months?
Alligator Bioscience AB lowest share price was kr0.17 and its highest was kr55.87 in the past 12 months.
What is Alligator Bioscience AB’s market cap?
Alligator Bioscience AB’s market cap is kr99.15M.
When is Alligator Bioscience AB’s upcoming earnings report date?
Alligator Bioscience AB’s upcoming earnings report date is May 05, 2026 which is in 68 days.
How were Alligator Bioscience AB’s earnings last quarter?
Alligator Bioscience AB released its earnings results on Feb 12, 2026. The company reported -kr0.663 earnings per share for the quarter, missing the consensus estimate of N/A by -kr0.663.
Is Alligator Bioscience AB overvalued?
According to Wall Street analysts Alligator Bioscience AB’s price is currently Overvalued.
Does Alligator Bioscience AB pay dividends?
Alligator Bioscience AB does not currently pay dividends.
What is Alligator Bioscience AB’s EPS estimate?
Alligator Bioscience AB’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Alligator Bioscience AB have?
Alligator Bioscience AB has 534,516,970 shares outstanding.
What happened to Alligator Bioscience AB’s price movement after its last earnings report?
Alligator Bioscience AB reported an EPS of -kr0.663 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -2.985%.
Which hedge fund is a major shareholder of Alligator Bioscience AB?
Currently, no hedge funds are holding shares in GB:0RK9
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Alligator Bioscience AB
Alligator Bioscience AB (publ), a research-based biotechnology company, develops antibody-based drugs for cancer treatment in Sweden. It develops products using its technology platforms, including ALLIGATOR-GOLD and ALLIGATOR-FAB, a proprietary human antibody library that contains approximately 60 billion unique antibody fragments; FIND, a molecular evolution technology for optimization of antibodies and other proteins; and RUBY, a bispecific antibody format. The company develops Mitazalimab, an immunostimulatory CD40 antibody, which has completed Phase I clinical trial for the treatment of metastatic cancer; and ATOR-1017, an immunostimulatory antibody, which is in phase I clinical trial that binds to the receptor 4-1BB in tumor-specific T cells. Its drug candidates in the preclinical development stage include ALG.APV-527, a bispecific 4-1BB and 5T4 antibody for the treatment of cancer. The company also holds a stake in clinical project Biosynergy (AC101), which is in phase I clinical trial. It has a partnership agreement with Aptevo Therapeutics Inc. for the co-development of ALG.APV-527; and a research collaboration with MacroGenics, Inc. to develop a novel immunotherapy. The company also has a joint research agreement with BioArctic AB (publ) to employ proprietary antibody generation technologies for developing new product candidates; and a research collaboration and license agreement with the Orion Corporation to discover and develop new bispecific antibody cancer therapeutics. Alligator Bioscience AB (publ) was incorporated in 2000 and is headquartered in Lund, Sweden.
Technical Analysis
Alzinova AB
―
Nanologica AB
―
Modus Therapeutics Holding AB
―
Active Biotech AB
―
NextCell Pharma AB
―